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Abstract
Background: The acute phase response (APR) is characterized by alterations in lipid and glucose metabolism leading to an
increased delivery of energy substrates. In adipocytes, there is a coordinated decrease in Free Fatty acids (FFAs) and glucose
storage, in addition to an increase in FFAs mobilization. Serum Amyloid A (SAA) is an acute phase protein mainly associated
with High Density Lipoproteins (HDL). We hypothesized that enrichment of HDL with SAA, during the APR, could be
implicated in the metabolic changes occurring in adipocytes.
Methodology/Principal Findings: In vitro differentiated human adipocytes (hMADS) were treated with SAA enriched HDL or
recombinant SAA and the metabolic phenotype of the cells analyzed. In hMADS, SAA induces an increased lipolysis through
an ERK dependent pathway. At the molecular level, SAA represses PPARc2, C/EBPa and SREBP-1c gene expression, three
transcription factors involved in adipocyte differentiation or lipid synthesis. In addition, the activation of the NF-kB pathway
by SAA leads to the induction of pro-inflammatory cytokines and chemokines, as in the case of immune cells. These latter
findings were replicated in freshly isolated mature human adipocytes.
Conclusions/Significance: Besides its well-characterized role in cholesterol metabolism, SAA has direct metabolic effects on
human adipocytes. These metabolic changes could be at least partly responsible for alterations of adipocyte metabolism
observed during the APR as well as during pathophysiological conditions such as obesity and conditions leading to insulin
resistant states.
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Introduction
The acute phase response (APR) induced during infection or
inflammation, is an early and highly complex reaction of the host,
which protects it from further injury. The APR is characterized by
an increased resting energy expenditure, extensive protein and fat
catabolism, negative nitrogen balance, hyperglycemia and hyper-
triglyceridemia [1,2]. The alterations in lipid and glucose
metabolism are linked to an impairment of insulin sensitivity [3].
Insulin resistance in muscles, liver and adipose tissue ensures a
high flow of glucose and Free Fatty Acids (FFAs) to the
predominantly energy-consuming cells, such as the inflammatory
and immune cells [4]. Glucose and FFAs uptake by muscles are
decreased while hepatic glucose and Very Low Density Lipopro-
teins (VLDL) productions are increased [1]. The hepatic-linked
hyperglycemia and hypertriglyceridemia produced throughout the
APR could be a consequence of alterations of adipose tissue
metabolism [5]. Indeed, in adipocytes, there is a coordinated
decrease in FFA storage and an increase in glycerol and FFA
mobilization through stimulation of lipolysis, which could
potentially affect hepatic metabolism [1]. The ‘‘insulin resistant’’
metabolic response observed during the APR shares some
similarities with the metabolic abnormalities linked to a variety
of very common disorders, such as diabetes, chronic renal failure,
atherosclerosis, obesity and metabolic syndrome [6–9]. Many of
these disorders are concomitant with a low grade inflammation
with changes in circulating proteins consistent with the profile
observed during the APR, although less pronounced.
Serum Amyloid A (SAA) is one of the major acute-phase
proteins predominantly produced by the liver [10]. The circulating
concentration of SAA protein is increased by 1000-fold within 24
to 48 h following infection/inflammation from a basal level of 5–
8 mg/mL. SAA is primarily transported in the plasma by High
Density Lipoproteins (HDL), for which it has a high affinity [11].
SAA is thought to be delivered by SAA-enriched HDL (saaHDL)
to the sites of infection where it can prime monocytes through its
cytokine-like properties [12–14]. In immune cells, SAA has been
shown to induce an inflammatory response through a variety of
receptors [15,16]. Plasmatic SAA is also more modestly elevated
(15–50 mg/mL) in chronic disorders characterized by increased
inflammation such as rheumatic diseases, atherosclerosis, diabetes
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enlarged adipocytes are a source of plasma SAA [21]. In addition,
recent data in stromavascular cells from human breast differen-
tiated in vitro in adipocytes, suggest that SAA could promote
lipolysis by decreasing perilipin expression and increasing
hormone sensitive lipase expression [22]. In porcine adipocytes,
SAA induces lipolysis by phosphorylating hormone sensitive lipase
(HSL) and by downregulating perilipin through extracellular
signal-regulated kinase (ERK) and protein kinase A (PKA)
dependent pathways [23].
We thus hypothesized that saaHDL, through SAA, could play a
major role in the alteration of adipocyte metabolism, providing a
molecular link between APR or low grade inflammatory disorders
and associated lipid and glucose metabolism abnormalities.
Methods
Materials
Human recombinant SAA was purchased from PeproTech
(Rocky Hill, NJ) and corresponds to human apoSAA1. Human
HDL, SAA-enriched HDL and BAY 11–7082 were from
Calbiochem. SAA content of SAA-enriched HDL was analyzed
by SDS-PAGE and found to be in the range of 8–10% of total
proteins. SAA and SAA-enriched HDL endotoxin content was
assessed using the LAL assay from Lonza and found to be less that
0.1 ng per mg (0.1 EU/mg). [c-
32P]ATP was from Amersham Life
Sciences. Primary antibodies for perilipin were from Progen
Biotechnik. All other primary antibodies and MEK1/2 inhibitor
PD95059 were from Cell Signaling. Secondary antibodies were
obtained from Rockland. All other chemicals were from Sigma,
including SB203580, SP600125 and H-89 inhibitors. For western-
blots, molecular weights were calculated by interpolation from
known standards (Bio-rad, Mu ¨nchen, Germany).
Cell culture
Adipocyte differentiation of Multipotent Adipose-Derived Stem
cells isolated from human adipose tissue (hMADS) was performed
as described previously [24,25] with the following modifications: 1)
unless stated, cells were cultivated in 96-well plates, 2) at post-
confluence, cells were induced into adipogenic differentiation
through DMEM/Ham F12 media supplemented with 0.86 mM
insulin, 0.2 nM T3, 10 mg/mL transferrin, 1 mM dexamethasone
(DEX), 100 mM IBMX and 200 nM GW7845, a PPARc agonist.
Three days later, the medium was changed and supplemented
with insulin, T3 and transferrin. Cells were used from day 7 to
day 12 post-induction.
Subcutaneous abdominal adipose tissue was obtained from
nondiabetic subjects who underwent plastic abdominal surgery at
the Department of General Surgery, St Louis hospital, Paris,
France. Samples were collected with the approval of the St Louis
Ethics Committee and all subjects gave their written consent.
Subjects on endocrine therapy or antihypertensive therapy and
patients with malignant diseases were excluded. Mature adipocytes
were isolated by the flotation method following 1h of collagenase
(Roche) digestion and several washes. 3.10
6 ells in DMEM 4.5 g/L
glucose with L-Glutamine, sodium pyruvate, 1 g/L BSA were
used within 24 h.
Adipocyte assays
Cytotoxicity was measured with the Lactate Dehydrogenase
Assay (Cayman). Lipolysis was evaluated by measuring glycerol
release from adipocytes using a Glycerol Colorimetric kit
(RANDOXH). Adipocytes were incubated in DMEM/F12
supplemented with 2 g/L low endotoxin BSA. Secreted adipo-
kines and cytokines were measured using ELISA kits according to
the manufacturers’ instructions (human MCP-1 and IL-6 kits:
Bender Medsystems; human IL-8, adiponectin and leptin).
RNA preparation and Real time quantitative PCR
(RTqPCR)
Total RNA was isolated using ABIPRISM 6100H (Applied
Biosystems), except for isolated mature adipocytes for which Total
RNA Isolation Kit (Macherey Nagel) was used. Levels of mRNA
were assessed by RTqPCR as described previously [26].
Oligonucleotides are given in Table S1. Data were normalized
using LRP10 RNA [27].
NF-kB and MAP Kinases signaling studies:
Upon stimulation with SAA (10 mg/mL), hMADS adipocytes
cultured in 6-well plates were rinsed briefly with ice-cold PBS. The
cells were scraped in 300 mL lysis buffer (Cell Signaling). The
lysates were passed through a 25-gauge needle and centrifuged at
20,0006g for 5 min at 4uC. Protein extracts were resolved on 4–
12% SDS-PAGE gel and transferred onto nitrocellulose mem-
branes. The fluorescent signals were detected using Odyssey
software system (v.2.1, Li-Cor). Electrophoretic Mobility Shift
Assays (EMSA) was performed as described previously [26].
Statistical Analysis:
Results are shown as means 6 S.D. Statistical significance was
determined using the Student’s t-test. Significance was set at
p,0.05. (Statistical significance: * p,0.05; ** p,0.01; ***p,0.001)
Results
SAA and saaHDL stimulate lipolysis
As already shown in human and porcine adipocytes, we found
that SAA and SAA-enriched HDL (saaHDL) were able to
stimulate lipolysis by a mechanism involving the phosphorylation
of HSL (results not shown).
SAA and saaHDL induce the secretion of cytokines and
chemokines but reduce adiponectin secretion
One important aspect of adipocyte function is the secretion of a
number of anti- or proinflammatory molecules. We then examined
the effects of both SAA and saaHDL on cytokine and chemokine
secretion in hMADS adipocytes following a 24 h treatment. SAA
dose-dependently induced MCP-1, IL-6 and IL-8 secretion
(Figure 1, panels A, C, E) while having no effect on TNFa and
SAA secretion (data not shown). Similar effects were observed for
saaHDL although the magnitude of secretion was lower at the
equivalent SAA dose of 10 mg/mL (Figure 1, panels B, D, F). We
also observed a slight increase in MCP-1 and IL-8 secretion with
increasing doses of HDL. This effect was not observed for IL-6.
In order to rule out the contribution of a potential SAA
endotoxin contamination to the stimulation of cytokines and
chemokines secreted by hMADS adipocytes, we have tested the
effect of SAA in the presence of a TLR-4 signaling inhibitor,
TAK-242 [28–29] and compare it to the effect of LPS
(lipopolysaccharide). TAK-242 completely abolished LPS-induced
MCP-1 and IL-6 secretion (Figure 2, panels A, C) whereas it had
no effect on SAA-induced MCP-1 and IL-6 secretion (Figure 2,
panels B,D). Therefore, these results confirm that the induction of
pro-inflammatory cytokines and chemokines by SAA is not due to
trace amounts of endotoxin in the recombinant human SAA.
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(data not shown). However, upon 72 h treatment we observed a
dose-dependent decrease in adiponectin secretion (up to 55%
inhibition at 30 mg/mL) (Figure 3, panel A) whereas leptin
secretion was not affected (Figure 3, panel C). Similar effects
were observed using saaHDL compared to normal HDL with a
70% decrease in adiponectin secretion and no effect on leptin
secretion (Figure 3, panels B and D).
Figure 1. SAA and saaHDL induce pro-inflammatory adipokine secretion by hMADS adipocytes. hMADS adipocytes were cultured in
presence or absence of human recombinant SAA (1, 3, 10 and 30 mg/mL), humans HDL and saaHDL (12.5, 25, 50 and 100 mg/mL) for 24 h. Upon
treatment, the supernatants were recovered and secreted concentrations of MCP-1 (Panels A and B), IL-6 (Panels C and D) and IL-8 (Panels E and F)
were measured by ELISA. Data are expressed as mean 6 SD from n=3–4 independent experiments. Statistical significance: * p,0.05; ** p,0.01, ***
p,0.001 vs. control.
doi:10.1371/journal.pone.0034031.g001
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To determine whether SAA-mediated alterations of adipocyte
metabolism were concomitant with changes in adipogenic gene
expression, we examined the effect of SAA on the expression of
two adipocyte transcription factors involved in adipocyte differ-
entiation, Peroxisome Proliferator Activated Receptor-gamma 2
(PPARc2, and CCAAT/Enhancer Binding Protein alpha (C/
EBPa and one involved in lipid synthesis, Sterol Regulatory
Element Binding Protein-1c (SREBP-1c). We also measured the
expression of several of their target genes. Dose-dependent
decreases in the expression of these three genes were apparent
after a 24 h treatment of hMADS with SAA (Figure 4, Panel A).
The mRNA levels of PPARc2 and SREBP-1c target genes such as
adiponectin, Glyceraldehyde 3-Phosphate Dehydrogenase
(G3PDH) and Fatty Acid Synthase (FAS) were also repressed
(Figure 4, Panel B). The mRNA levels of the glucose transporter
GLUT4 were downregulated (50% inhibition at 30 mg/mL)
(Figure 4, Panel B), potentially inducing a decreased insulin
stimulated glucose transport in adipocytes. In contrast, insulin
receptor expression was not affected (results not shown). We finally
looked at the mRNA levels of Monocyte Chemoattractant Protein-
1 (MCP-1), SAA, haptoglobin and Plasminogen Activator
Inhibitor-1 (PAI-1). With the exception of PAI-1 (data not shown),
mRNA levels of other adipokines (MCP-1, Haptoglobin and SAA)
were dose-dependently increased (Figure 4, Panel C).
SAA activates NF-kB and MAPK signaling pathways
We then addressed the potential intracellular signalling
pathways involved in the metabolic and gene alterations induced
by SAA. Since SAA induces NF-kB and MAPK signaling
pathways in immune cells, we examined these early signaling
events by treating hMADS adipocytes with SAA (10 mg/mL) for
up to 1 h. In order to determine whether SAA activates the NF-kB
pathway, an electromobility shift assay was performed using
nuclear extracts of hMADs adipocytes treated with SAA or with
TNFa as a positive control. SAA stimulated the translocation of
Figure 2. SAA pro-inflammatory effects in hMADS adipocytes are not due to endotoxin contamination. Fully differentiated hMADS
adipocytes were preincubated with or without 2 mM TAK-242 inhibitor for 1 h. Upon preincubation, cells were treated in the presence or absence of
recombinant human SAA (1, 3 and 10 mg/mL) or LPS (1, 3 and 10 ng/mL) for 24 h. At the end of the treatment period, the supernatants were
recovered and secreted MCP-1 (Panels A and B) and IL-6 (Panels C and D) were measured by ELISA. Data are expressed as mean 6 SD from 3
independent experiments.
doi:10.1371/journal.pone.0034031.g002
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15 min in a way very similar to TNFa (Figure 5, panel A). We
next examined the phosphorylation status of MAPK (p44/42,
JNK and p38). SAA induced p44/42, p38, and p46/54-JNK
phosphorylation (Figure 5, panel B). A similar response for the
phosphorylation of p46/54-JNK was observed using TNFa as
shown previously in macrophages [30]. In conclusion, SAA is able
to induce NF-kB and MAPK signaling pathways in human
adipocytes.
Inflammation induced by SAA is blocked by inhibiting
the NF-kB pathway
To determine whether the induction of proinflammatory factors
is a consequence of the activation of these signaling pathways, we
used SB203580, a p38 inhibitor, PD98059, a MEK1/2 inhibitor,
SP600125, a JNK inhibitor and BAY11-7082, an inhibitor of IkB-
alpha phosphorylation. Only BAY11-7082 (10 mM), a JNK
inhibitor was able to inhibit IL-8 secretion induced by SAA, IL-
6 secretion (data not shown) and MCP-1expression (Figure 5,
panel C and D). Cell viability assessed by LDH release was not
affected by incubation with both SAA and the various inhibitors
(results not shown).
SAA effect on lipolysis is blocked by inhibiting the ERK
pathway
While BAY11-7082 blunted SAA-induced MCP-1 gene expres-
sion (Figure 5, panel D), it failed both to prevent SAA stimulated
lipolysis and to restore PPARc2, C/EBPa and SREBP-1 c gene
expression (data not shown) suggesting that the metabolic effects
induced by SAA are direct and not an indirect consequence of its
inflammatory effects. The various inhibibitors were unable to
antagonize the lipolytic effects of SAA except for the MEK-1
inhibitor which completely blunted SAA stimulated lipolysis
(Figure 5, panel E and results not shown) indicating that as
previously described [23], SAA stimulates lipolysis through the
ERK pathway.
Figure 3. SAA and saaHDL decrease adiponectin secretion by hMADS adipocytes. hMADS adipocytes were cultured in the presence or
absence of human recombinant SAA (1, 3, 10 and 30 mg/mL), humans HDL and saaHDL (12.5, 25, 50 and 100 mg/mL) for 3 days following which
secreted adiponectin (Panels A and B) and leptin (Panels C and D) were measured by ELISA. Data are expressed as mean 6 SD from 3 independent
experiments. Statistical significance: * p,0.05; *** p,0.001 vs. control.
doi:10.1371/journal.pone.0034031.g003
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markers in freshly isolated mature adipocytes
In order to confirm the effects of SAA in human adipocytes, we
have analysed the effects of SAA on freshly isolated mature human
adipocytes from subcutaneous adipose tissue following a 24 h
treatment. A low dose (1 mg/mL) of SAA resulted in a maximal
induction of IL-6 secretion (Figure 6, panel A) as well as IL-8 and
MCP-1(data not shown) and suppression of PPARc2, C/EBPa
and SREBP-1c (Figure 6, panel B), showing that the action of SAA
is not restricted to the adipocyte cell line.
Figure 4. SAA decreases the expression of adipocyte markers. hMADS adipocytes were cultured in the presence or absence of human
recombinant SAA (1, 3, 10 and 30 mg/mL) for 24 h. Upon treatment, total RNA was extracted and expression levels of various genes were analyzed by
RTqPCR. Panel A: three important transcription factor (PPARc2, C/EBPa and SREBP-1c). Panel B: lipogenic genes and adiponectin. Panel C:
inflammation related proteins. The mRNA levels, normalized to LRP10 RNA expression, were determined relative to untreated control cells. Data are
expressed as mean 6 SD from n=3–5 independent experiments. Statistical significance: * p,0.05; ** p,0.01; *** p,0.001 vs. control.
doi:10.1371/journal.pone.0034031.g004
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In this study, we demonstrate that beside its effects on
cholesterol metabolism and transport [10], SAA has direct effects
on adipocytes, which can contribute to the overall metabolic and
cytokine changes observed during APR. Although SAA concen-
tration during APR can reach concentrations as high as 1 mg/mL,
we show here that at much lower concentrations (1 to 30 mg/mL),
Figure 5. SAA activates NF-kB and MAPK pathways and NF-kB inhibition suppresses inflammation. hMDAS adipocytes were stimulated
with 2 mg/mL recombinant human SAA or 5 ng/mL TNFa (positive control) for different periods of time. Nuclear proteins were extracted and EMSA
performed as described in ‘‘Materials and Methods’’. The NF-kB/DNA complex was detected by [c-
32P]-labeled NF-kB probe (Panel A). Total proteins
were also extracted to determine total and phosphorylated forms of MAP kinases, p44/42, p38 and SAPK/JNK (Panel B). Following a 48 h insulin
deprivation, hMADS adipocytes were incubated for 1 h with various inhibitors (10 mM) and subsequently incubated for 6 h and 24 h with SAA
(10 mg/mL). SB203580, a p38 inhibitor; SP600125, a JNK inhibitor; PD98059, a MEK1/2 inhibitor; BAY11-7082, an inhibitor of IkB-alpha
phosphorylation. At the end of the treatment period, the supernatants were recovered. Secreted IL-8 (Panel C) was measured by ELISA. MCP-1 gene
expression was analyzed by RT-qPCR (Panel D). Glycerol was measured in the cell supernatant using a colorimetric assay (Panel E). * p,0.05; **
p,0.01; *** p,0.001 vs. control.
doi:10.1371/journal.pone.0034031.g005
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clear-cut effects on adipocytes and could also contribute to the
metabolic and endocrine characteristics of obesity.
During APR, there is a decrease in the capacity of adipose tissue
to store FFAs. Our data suggests that the decrease in lipid content
is a consequence of several effects of SAA on adipocytes such as 1)
decrease in gene expression of transcription factors important for
adipocyte storage such as PPARc2, C/EBPaand SREBP-1c; 2)
decrease in gene expression of the main enzymes involved in
lipogenesis like G3PDH and FAS; 3) increase in lipolysis through
activation of the ERK pathway and HSL as previously described
also in other models [22,23]. Since SAA strongly reduces the
expression of the glucose transporter GLUT4 in adipocytes, a
decreased fatty acid storage capacity could be also the conse-
quence of a reduced glucose uptake since glucose is necesssary for
the synthesis of a-glycerophosphate, which forms the backbone of
triglycerides. It remains to show however that insulin-induced
glucose transport is indeed affected by SAA in adipocytes. A
stimulated lipolysis and a decreased glucose transport in the
presence of SAA by counteracting insulin action could ultimately
participate to the impairment of adipose tissue insulin sensitivity
[31] observed during APR.
Given that SAA is a pro-inflammatory cytokine on immune
cells, we studied the adipokines secretion profile of human
adipocytes [12]. We demonstrate that both saaHDL and SAA
induce the expression and secretion of pro-inflammatory proteins
such as MCP-1, IL-6 and IL-8, while adiponectin secretion is
repressed. This secretion profile is the hallmark of hypertrophic
adipocyte [32]. Several studies in obese humans have shown that
adipose tissue expression of SAA appears to be restricted to
adipocytes and in particular to hypertrophic adipocytes [17,21].
Plasma SAA levels are also increased in human obesity in a range
compatible with the metabolic effects observed in this study
[17,33,34]. Therefore, besides the induction of changes in
adipocyte metabolism by SAA during APR, pathophysiological
exposure of adipocytes to SAA could directly contribute to the
establishment of the inflammatory and insulin resistant phenotype
in adipose tissue in obese patients [34].
In humans, SAA1 is mainly produced by the liver during the
APR, while in obesity adipocytes contribute to the plasma SAA
levels [35–37]. In murine models, SAA3 is upregulated by diet-
induced obesity in adipocytes [38–40]. SAA3 has been shown
recently to form a complex with hyaluronan suggesting that it is
trapped in the extracellular matrix [41]. These complexes facilitate
recruitment, adhesion and retention of monocyte-macrophages
within adipose tissue, a characteristic of obese adipose tissue.
We previously reported that SAA is a player in the dialogue
between hypertrophied adipocytes and macrophages through its
regulation of adipocyte cholesterol efflux [42]. Taken together, our
new data along with the published observation provide further
evidence for a central role of SAA in adipocyte-macrophage cross-
talks in obesity: 1) SAA increases IL-6 and IL-8 production by
adipocytes as well as the chemokine MCP-1, which recruits
circulating monocytes into the adipose tissue; 2) SAA increases IL-
6, IL-8 and TNFa production by immune cells; 3) SAA displays
direct chemoattractant activity in the presence or absence of
hyaluronan complexes [15,33,41–44].
This is the first study to address the early SAA intracellular
signaling pathways in human adipocytes which demonstrates that
SAA activates NF-kB and MAPK signaling pathways (p44/42,
p38 and p46-JNK) in these cells. Furthermore, BAY-117082, a
NF-kB pathway inhibitor, completely blunted SAA-induced
inflammation while PD98059, an ERK pathway inhibitor blunted
SAA-induced lipolysis. A majority of studies has shown that SAA
signals through a seven transmembrane G-coupled receptor
FPRL1 leading to NF-kB and MAPK pathways activation whilst
other reports suggest that SAA could also bind and signal through
Scavenger Receptor class B type I (SR-BI/CLA-1) at least for
MAPK activation [15,44–46]. In Rheumatoid Arthritis patients,
SAA has been shown to bind and activate the Receptor for
Advanced Glycation End-products (RAGE) [47]. Some studies
have suggested that TLR4 may mediate SAA signaling [48].
However given the fact that TAK-242, a TLR-4 signaling
inhibitor did not block SAA mediated inflammation in adipocytes,
it is unlikely that TLR4 is involved in SAA signaling in adipocytes.
A fourth SAA receptor has also been suggested: Tanis/SelS whose
Figure 6. SAA exerts pro-inflammatory effects in adipocytes isolated from human subcutaneous adipose tissue. Isolated human
adipocytes were prepared as described in ‘‘Methods’’ and were cultured for 24 h in presence or absence of human recombinant SAA (1, 3, 10 and
30 mg/mL). Secreted IL-6 (Panel A) was measured by ELISA. Gene expression levels of PPARc2, C/EBPa and SREBP-1c were analyzed by RT-qPCR
(Panel B). The mRNA levels normalized to LRP10 RNA expression were determined relative to untreated control cells. Statistical significance: * p,0.05;
** p,0.01; *** p,0.001 vs. control for three preparations.
doi:10.1371/journal.pone.0034031.g006
Serum Amyloid A and Adipocyte Metabolism
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e34031expression has been linked to glucose and triglyceride levels in an
animal model of type 2 diabetes and metabolic syndrome
Psammomys obesus [49], could be a candidate for the metabolic
effects of SAA in human adipocytes. However, the receptor(s)
mediating the effect of SAA in adipocytes still remain to be
identified.
We have extended these results to mature human adipocytes
freshly isolated from subcutaneous adipose tissue. In mature
human adipocytes, a low dose of SAA (1 mg/mL) was able to
confer a maximal induction of inflammation as well as a maximal
repression of the transcription factors (PPARc2, C/EBPa and
SREBP-1c) suggesting higher SAA receptor expression.
In summary, our data suggest that SAA could be at least partly
responsible for the metabolic changes of the adipose tissue during
the APR. At the molecular level, SAA represses the gene
expression of PPARc2, C/EBPa and SREBP-1c, three important
transcription factors. In addition, SAA activates the NF-kB
pathway leading to the induction of inflammation. These effects
could translate into a phenotype characterized by a coordinated
decrease in the storage of FFAs and an increase in FFAs
mobilization and at least partly explain the reduced insulin
efficiency concomitant with APR. Our findings also reveal that in
conditions of low grade inflammation such as obesity, SAA could
participate to the metabolic phenotype characterized by adipose
tissue inflammation, insulin resistance and fatty acid overflow from
adipocytes.
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